Site-specific PEGylation endows a mammalian ribonuclease with antitumor activity

Cancer Biology and Therapy

Volumn 12, Issue 3, 2011, Pages 208-214

  Rutkoski, Thomas J ^a   Kink, John A ^b   Strong, Laura E ^b   Raines, Ronald T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Quintessence Biosciences Inc   (United States)

Author keywords

Bioconjugation; Biologic drug; Cancer; Cytotoxin; Pharmacokinetics; Poly(ethylene glycol); Ribonuclease; Ribonuclease inhibitor; Site directed mutagenesis; Xenograft

Indexed keywords

BOVINE SERUM ALBUMIN; DOCETAXEL; MACROGOL; PANCREATIC RIBONUCLEASE; RIBONUCLEASE A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONJUGATION; CONTROLLED STUDY; CYTOSOL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; LOW DRUG DOSE; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSOL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; HALF-LIFE; HUMANS; MALE; MICE; PLACENTAL HORMONES; POLYETHYLENE GLYCOLS; PROTEIN CONFORMATION; RIBONUCLEASE, PANCREATIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79961233774     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.3.15959     Document Type: Article

References (50)

1. Arnold U, Ulbrich-Hofmann R. Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 2006; 28:1615-22; DOI: 10.1007/s10529-006-9145-0.
2. Lee JE, Raines RT. Ribonucleases as novel chemotherapeutics: The ranpirnase example. BioDrugs 2008; 22:53-8; DOI: 10.2165/00063030-200822010- 00006.
3. Fang EF, Ng TB. Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim Biophys Acta 2011;1815:65-74.
4. Murthy BS, Sirdeshmukh R. Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor. Biochem J 1992; 281:343-8.
5. Boix E, Wu Y, Vasandani VM, Saxena SK, Ardelt W, Ladner J, et al. Role of the N terminus in RNase A homologues: Differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. J Mol Biol 1996; 257:992-1007; DOI: 10.1006/jmbi.1996.0218.
6. Rutkoski TJ, Kurten EL, Mitchell JC, Raines RT. Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A. J Mol Biol 2005; 354:41-54; DOI: 10.1016/j.jmb.2005.08.007.
7. Rutkoski TJ, Raines RT. Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Curr Pharm Biotechnol 2008; 9:185-9; DOI: 10.2174/138920108784567344.
8. Matoušek J, Souček J, Slavík T, Tománek M, Lee JE, Raines RT. Comprehensive comparison of the cytotoxic activities of onconase and bovine seminal ribonuclease. Comp Biochem Physiol C Toxicol Pharmacol 2003; 136:343-56; DOI: 10.1016/j.cca.2003.10.005.
9. Gad SC. Handbook of Pharmaceutical Biotechnology. Hoboken NJ: John Wiley and Sons, Inc.; 2007.
10. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2:214-21; DOI: 10.1038/nrd1033.
11. Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003; 55:217-50; DOI: 10.1016/S0169-409X(02)00180-1.
12. Fishburn CS. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97:4167-83; DOI: 10.1002/jps.21278.
13. Pasut G, Sergi M, Veronese FM. Anti-cancer PEGenzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 2008; 60:69-78; DOI: 10.1016/j.addr.2007.04.018.
14. Veronese FM, Largajolli R, Boccu E, Benassi CA, Schiavon O. Surface modification of proteins. Activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase. Appl Biochem Biotechnol 1985; 11:141-52; DOI: 10.1007/BF02798546.
15. Caliceti P, Schiavon O, Veronese FM, Chaiken IM. Effects of monomethoxypoly(ethylene glycol) modification of ribonuclease on antibody recognition, substrate accessibility and conformational stability. J Mol Recognit 1990; 3:89-93; DOI: 10.1002/jmr.300030206.
16. Schiavon O, Caliceti P, Sartore L, Veronese FM. Surface modification of enzymes for therapeutic use: Monomethoxypoly(ethylene glycol) derivatization of ribonuclease. Farmaco 1991; 46:967-78.
17. Matoušek J, Poucková P, Souček J, Škvor J. PEG chains increase aspermatogenic and antitumor activity of RNase A and BS-RNase enzymes. J Control Release 2002; 82:29-37; DOI: 10.1016/S0168-3659(02) 00082-2.
18. Matoušek J, Poucková P, Hloušková D, Zadinová M, Souček J, Škvor J. Effect of hyaluronidase and PEG chain conjugation on the biologic and antitumor activity of RNase A. J Control Release 2004; 94:401-10; DOI: 10.1016/j.jconrel.2003.10.025.
19. Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris JM, Veronese FM. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 1995; 6:62-9; DOI: 10.1021/bc00031a006.
20. Murdock AL, Grist KL, Hirs CHW. On the dinitrophenylation of bovine pancreatic ribonuclease A. Kinetics of the reaction in water and 8 M urea. Arch Biochem Biophys 1966; 114:375-90; DOI: 10.1016/0003-9861(66)90350-X.
21. Messmore JM, Fuchs DN, Raines RT, Ribonuclease A. Revealing structure-function relationships with semisynthesis. J Am Chem Soc 1995; 117:8057-60; DOI: 10.1021/ja00136a001.
22. Kim JS, Souček J, Matoušek J, Raines RT. Catalytic activity of bovine seminal ribonuclease is essential for its immunosuppressive and other biological activities. Biochem J 1995; 308:547-50.
23. Bretscher LE, Abel RL, Raines RT. A ribonuclease A variant with low catalytic activity but high cytotoxicity. J Biol Chem 2000; 275:9893-6; DOI: 10.1074/jbc.275.14.9893.
24. Futami J, Maeda T, Kitazoe M, Nukui E, Tada H, Seno M, et al. Preparation of potent cytotoxic ribonucleases by cationization: Enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry 2001; 40:7518-24; DOI: 10.1021/bi010248g.
25. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 2002; 54:531-45; DOI: 10.1016/S0169- 409X(02)00026-1.
26. Johnson RJ, Chao TY, Lavis LD, Raines RT. Cytotoxic ribonucleases: The dichotomy of coulombic forces. Biochemistry 2007; 46:10308-16; DOI: 10.1021/bi700857u.
27. Leland PA, Schultz LW, Kim BM, Raines RT. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci USA 1998; 95:10407-12; DOI: 10.1073/pnas.95.18.10407.
28. Kothandaraman S, Hebert MC, Raines RT, Nibert ML. No role for pepstatin-A-sensitive acidic proteinases in reovirus infections of L or MDCK cells. Virology 1998; 251:264-72; DOI: 10.1006/viro.1998.9434.
29. Abel RL, Haigis MC, Park C, Raines RT. Fluorescence assay for the binding of ribonuclease A to the ribonuclease inhibitor protein. Anal Biochem 2002; 306:100-7; DOI: 10.1006/abio.2002.5678.
30. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994; 83:601-6; DOI: 10.1002/jps.2600830432.
31. Kurfürst MM. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 1992; 200:244-8; DOI: 10.1016/0003-2697(92)90460-O.
32. Chao TY, Lavis LD, Raines RT. Cellular uptake of ribonuclease A relies on anionic glycans. Biochemistry 2010; 49:10666-73; DOI: 10.1021/bi1013485.
33. Klink TA, Raines RT. Conformational stability is a determinant of ribonuclease A cytotoxicity. J Biol Chem 2000; 275:17463-7; DOI: 10.1074/jbc.M001132200.
34. Rutkoski TJ, Kink JA, Strong LE, Schilling CI, Raines RT. Antitumor activity of ribonuclease multimers created by site-specific covalent tethering. Bioconjug Chem 2010; 21:1691-702; DOI: 10.1021/bc100292x.
35. Tarnowski GS, Kassel RL, Mountain IM, Blackburn P, Wilson G, Wang D. Comparison of antitumor activities of pancreatic ribonuclease and its cross-linked dimer. Cancer Res 1976; 36:4074-8.
36. Venkatachalam MA, Rennke HG. The structural and molecular basis of glomerular filtration. Circ Res 1978; 43:337-47. (Pubitemid 9019758)
37. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D. Renal filtration, transport and metabolism of low-molecular- weight proteins: A review. Kidney Int 1979;16:251-70; DOI: 10.1038/ki.1979.128.
38. Haigis MC, Kurten EL, Abel RL, Raines RT. KFERQ sequence in ribonuclease A-mediated cytotoxicity. J Biol Chem 2002; 277:11576-81; DOI: 10.1074/jbc.M112227200.
39. Haigis MC, Kurten EL, Raines RT. Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res 2003; 31:1024-32; DOI: 10.1093/nar/gkg163.
40. Soncin F, Strydom DJ, Shapiro R. Interaction of heparin with human angiogenin. J Biol Chem 1997; 272:9818-24; DOI: 10.1074/jbc.272.15.9818.
41. Fuchs SM, Raines RT. Internalization of cationic peptides: The road less (or more?) traveled. Cell Mol Life Sci 2006; 63:1819-22; DOI: 10.1007/s00018-006-6170-z.
42. Turcotte RF, Lavis LD, Raines RT. Onconase cytotoxicity relies on the distribution of its positive charge. FEBS J 2009; 276:3846-57; DOI: 10.1111/j.1742-4658.2009.07098.x.
43. Johnson RJ, McCoy JG, Bingman CA, Phillips GN Jr, Raines RT. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. J Mol Biol 2007; 368:434-49; DOI: 10.1016/j.jmb.2007.02.005.
44. Ribó M, Beintema JJ, Osset M, Fernández E, Bravo J, de Llorens R, et al. Heterogeneity in the glycosylation pattern of human pancreatic ribonuclease. Biol Chem Hoppe Seyler 1994; 375:357-63. (Pubitemid 2089218)
45. Kelemen BR, Klink TA, Behlke MA, Eubanks SR, Leland PA, Raines RT. Hypersensitive substrate for ribonucleases. Nucleic Acids Res 1999; 27:3696-701; DOI: 10.1093/nar/27.18.3696.
46. Smith BD, Soellner MB, Raines RT. Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid). J Biol Chem 2003; 278:20934-8; DOI: 10.1074/jbc.M301852200.
47. delCardayré SB, Raines RT. Structural determinants of enzymatic processivity. Biochemistry 1994; 33:6031-7; DOI: 10.1021/bi00186a001.
48. a of fluorescein to optimize binding assays. Anal Chem 2007; 79:6775-82; DOI: 10.1021/ac070907g.
49. Lee FS, Shapiro R, Vallee BL. Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor. Biochemistry 1989; 28:225-30; DOI: 10.1021/bi00427a031.
50. Kobe B, Deisenhofer J. Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A. J Mol Biol 1996; 264:1028-43; DOI: 10.1006/jmbi.1996.0694.